pharma · SBRT · Covid19 · GRTX
Kailera Therapeutics
Galera Therapeutics
Kailera Therapeutics trial registry — 17 ClinicalTrials.gov studies with program phase, status, and indication context.
Waltham, Massachusetts, United States HQ
2024 Founded
153 Employees
Public company Type
GRTX · NYSE Ticker
Company details
- Status
- Public
- HQ
- Waltham, Massachusetts, United States
- Founded
- 2024
- Employees
- 153
- Programs
- 17
- Drugs
- 7
- Patents
- 23
Kailera Therapeutics clinical trials
Registry index of 17 ClinicalTrials.gov studies linked to Kailera Therapeutics programs — each row shows trial ID, program name, phase, status, and indication.
Kailera Therapeutics trial registry — 17 ClinicalTrials.gov studies with program phase, status, and indication context.
Recent trial activity
Latest clinical program signals indexed for Kailera Therapeutics.
-
Low Dose GC4419: 30mg/day — Phase 2
Clinical update -
Dextromethorphan HBr — Phase 1
Clinical update -
GC4711 Oral Capsule G-101 — Phase 1
Clinical update -
GC4702 dry powder — Phase 1
Clinical update -
GC4419 90mg — Phase 3
Clinical update -
Drug GC4711 — Phase 2
Clinical update -
Drug: GC4419 — Phase 2
Clinical update -
GC4419 — Phase 2
Clinical update